Merck study results signal blood cancer potential for new type of immunotherapy
Bio Pharma Dive
MAY 26, 2022
Bristol Myers beat Merck to the first approval of a so-called LAG-3 inhibitor. But Merck is advancing its own and data to be presented at ASCO show it could help treat Hodgkin's lymphoma
Let's personalize your content